Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.73 |
| ▸ | AURKA | O14965 | 1/20 | 0.73 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.73 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.73 |
| ▸ | GSK3A | P49840 | 1/20 | 0.73 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.73 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.73 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.73 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.73 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.73 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.73 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.56 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16109510 | 0.86 | CHEK1 (0.55) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL10078940 | 0.81 | CHEK1 (0.70) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL12060146 | 0.81 | CHEK1 (0.66) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL31691580 | 0.81 | CHEK1 (0.49) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL952561 | 0.79 | CHEK1 (0.47) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL3638105 | 0.79 | CHEK1 (0.47) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL30457321 | 0.79 | CHEK1 (0.67) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL625971 | 0.77 | TAOK1 (0.65) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| Fumaric Acid SCHEMBL530257 | 0.77 | CHEK1 (0.60) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| Maleic Acid SCHEMBL530256 | 0.77 | CHEK1 (0.60) | CHEK1AURKADAPK3CSNK1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| CN-104822676-B | Novel ROCK inhibitors | PH制药有限公司 | 2019-11-05 | — | — | CN | disclosed |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-9440961-B2 | Rho-kinase inhibitors and method of preparation | SURFACE LOGIX, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150344464-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | KADMON CORPORATION, LLC | 2015-12-03 | — | — | US | disclosed |
| CN-1812973-B | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMA CO LTD | 2010-12-22 | — | — | CN | disclosed |
| WO-2010104851-A1 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| EP-2170865-A2 | NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009010660-A2 | SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF, AND USE OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008094909-A2 | QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1865958-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | Surface Logix, Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105081-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| CN-1812973-A | Indazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICAL CO LTD (US) | 2006-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | CHEK1 1114/4885AURKA 1412/4885DAPK3 714/4885 |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | CHEK1 1114/4885AURKA 1412/4885DAPK3 714/4885 |
| US-20150344464-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | CHEK1 1114/4885AURKA 1412/4885DAPK3 714/4885 |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | CHEK1 1114/4885AURKA 1412/4885DAPK3 714/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | CHEK1 2137/4885AURKA 1678/4885DAPK3 2040/4885 |
| US-20100144707-A1 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | CHEK1 1114/4885AURKA 1412/4885DAPK3 714/4885 |
| US-10570123-B2 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | CHEK1 1114/4885AURKA 1412/4885DAPK3 714/4885 |
| US-20190276440-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | CHEK1 2227/4885AURKA 1051/4885DAPK3 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.